Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer
October 02 2019 - 7:00AM
Business Wire
Accomplished CMO Brings Deep Clinical Drug
Development Expertise from Leading Biotech and Pharma Companies
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH),
a clinical-stage biopharmaceutical company addressing key
mechanisms of tumor drug resistance, today announced that it has
appointed Matthew L. Sherman, M.D. as Executive Vice President and
Chief Medical Officer. Dr. Sherman brings over 25 years of
experience as a physician-scientist in clinical drug development in
oncology and hematology at leading biotechnology and pharmaceutical
companies. Dr. Sherman will be responsible for leading the clinical
development and medical affairs strategy for the Company’s pipeline
of small molecule drug candidates designed using its proprietary
kinase switch control inhibitor platform.
“We are thrilled to welcome Matt to the Deciphera team at this
exciting time for our company,” said Steve Hoerter, President and
Chief Executive Officer of Deciphera. “Matt’s deep expertise in
successfully developing oncology therapeutics will be an incredible
asset to Deciphera as we prepare the new drug application, or NDA,
for ripretinib and advance our pipeline of novel product
candidates. I look forward to working with Matt as we continue our
mission to develop important new medicines for the treatment of
cancer.”
“Deciphera’s proprietary kinase switch control inhibitor
platform has generated a diverse portfolio of product candidates
spanning late-stage to preclinical development that are designed to
address unmet needs in the treatment of cancer,” said Dr. Sherman.
“I am excited to join Deciphera and its impressive leadership team
at this pivotal moment for the Company, and I look forward to
contributing to its future success.”
From 2006 to 2018, Dr. Sherman served as Chief Medical Officer
of Acceleron Pharma, Inc., where he led medical research, clinical
operations, biostatistics, data management, clinical pharmacology,
medical writing, outsourcing and pharmacovigilance. Before joining
Acceleron, Dr. Sherman was Senior Vice President and Chief Medical
Officer at Synta Pharmaceuticals (now Madrigal Pharmaceuticals).
Prior to Synta, Dr. Sherman spent over a decade at Wyeth-Ayerst
Research/Genetics Institute, where he led the successful
submission, positive Oncologic Drug Advisory Committee
recommendation, and FDA approval for the first antibody immune-drug
conjugate for acute myeloid leukemia. He has published 260 original
papers, book chapters, reviews and abstracts, and is listed as an
inventor on 13 patents. He currently serves as a director of Pieris
Pharmaceuticals, Pulmatrix, and NewLink Genetics. He also serves on
the Geisel School of Medicine at Dartmouth Board of Advisors and
Alumni Council. Dr. Sherman received a S.B. in Chemistry from the
Massachusetts Institute of Technology and a M.D. from Dartmouth
Medical School. He completed his internal medicine residency at
Georgetown University Medical Center and fellowship in Medical
Oncology at the Dana-Farber Cancer Institute. Dr. Sherman is board
certified in Internal Medicine and Medical Oncology and has held
various academic and teaching positions at Harvard Medical School
with corresponding clinical appointments at the Dana-Farber Cancer
Institute and Brigham and Women’s Hospital in Boston.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
addressing key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse
pipeline of tumor-targeted and immuno-targeted drug candidates
designed to improve outcomes for patients with cancer by improving
the quality, rate and/or durability of their responses to
treatment.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding efforts to prepare for our planned NDA submission with
ripretinib for patients with advanced gastrointestinal stromal
tumors who have failed all currently available therapies, the
potential for ripretinib to provide benefit, including, without
limitation, in earlier lines of therapy, and the potential to
advance our earlier stage pipeline candidates. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks and
uncertainties related to the delay of any current or planned
clinical studies or the development of our drug candidates,
including ripretinib, our ability to successfully demonstrate the
efficacy and safety of our drug candidates including in later-stage
studies, the preclinical and clinical results for our drug
candidates, which may not support further development of such drug
candidates, our ability to timely complete and prepare the
information required for and file an NDA for ripretinib, our
ability to manage and our reliance on third parties such as our
third party drug substance and drug product contract manufacturers,
actions of regulatory agencies, any or all of which may affect the
initiation, timing and progress of clinical studies and the timing
of and our ability to obtain regulatory approval, if at all, and
make our investigational drugs available to patients, and other
risks identified in our SEC filings, including our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2019, and subsequent
filings with the SEC. We caution you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005188/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners David.Rosen@argotpartners.com
212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Sep 2023 to Sep 2024